Tag: Servier

March 9, 2017 Off

Servier cleared for UCART development in the USA

By Dino Mustafić

Servier has been cleared with Investiga New Drug (IND) by the U.S. Food and Drug Administration (FDA) for the clinical development of UCART19, an allogeneic, gene-edited cellular therapy candidate to treat relapsed/refractory acute lymphoblastic leukemia.

October 7, 2015 Off

Horizon In-licenses Oncology Programme from Servier and Enters Option Agreement

By Dino Mustafić

Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, has announced that its leveraged business unit has signed a programme in-licensing and option agreement with Servier, the independent French research-based pharmaceutical company .